A PYMNTS Company

US: Pay-for-delay lawsuit hits acne medication company

By  |  August 29, 2013

A slew of pharmaceutical companies are facing a lawsuit regarding their alleged delay of the generic form of an acne medication from reaching the shelves, following a recent trend of suits involving pay-for-delay agreements.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    A class action lawsuit was filed last Wednesday in federal court in Pennsylvania against makers of the drug, who are accused of harming competition through the delay of the generic form of the drug called Solodyn.

    Court documents list Lupin Pharmaceuticals, Impax and other major drug companies as defendants.

    The US Supreme Court ruled last June that such pay-for-delay agreements are a valid reason for filing a lawsuit, leading to a new influx of similar lawsuits.

    Full Content: The Pennsylvania Record

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.